207 related articles for article (PubMed ID: 17709915)
1. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
Yilmaz MI; Saglam M; Sonmez A; Caglar K; Cakir E; Kurt Y; Eyileten T; Tasar M; Acikel C; Oguz Y; Vural A; Yenicesu M
Blood Purif; 2007; 25(4):327-35. PubMed ID: 17709915
[TBL] [Abstract][Full Text] [Related]
2. Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?
Yilmaz MI; Sonmez A; Saglam M; Yaman H; Cayci T; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Yenicesu M; Axelsson J
Nephrol Dial Transplant; 2010 Oct; 25(10):3250-6. PubMed ID: 20348148
[TBL] [Abstract][Full Text] [Related]
3. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
4. Lowering asymmetric dimethylarginine--a new mechanism mediating the renoprotective effects of renin-angiotensin system inhibitors in proteinuric patients?
Kielstein JT; Fliser D
Blood Purif; 2007; 25(4):324-6. PubMed ID: 17709914
[No Abstract] [Full Text] [Related]
5. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
Eyileten T; Sonmez A; Saglam M; Cakir E; Caglar K; Oguz Y; Vural A; Yenicesu M; Yilmaz MI
Nephrology (Carlton); 2010 Mar; 15(2):225-9. PubMed ID: 20470283
[TBL] [Abstract][Full Text] [Related]
6. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
7. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
8. Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria.
Bilić M; Munjas-Samarin R; Ljubanović D; Horvatić I; Galesić K
Coll Antropol; 2011 Dec; 35(4):1061-6. PubMed ID: 22397239
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.
Gamboa JL; Pretorius M; Sprinkel KC; Brown NJ; Ikizler TA
BMC Nephrol; 2015 Oct; 16():167. PubMed ID: 26494370
[TBL] [Abstract][Full Text] [Related]
10. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
[TBL] [Abstract][Full Text] [Related]
11. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
[TBL] [Abstract][Full Text] [Related]
12. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease.
Caglar K; Yilmaz MI; Sonmez A; Cakir E; Kaya A; Acikel C; Eyileten T; Yenicesu M; Oguz Y; Bilgi C; Oktenli C; Vural A; Zoccali C
Kidney Int; 2006 Aug; 70(4):781-7. PubMed ID: 16820789
[TBL] [Abstract][Full Text] [Related]
13. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.
Yilmaz MI; Axelsson J; Sonmez A; Carrero JJ; Saglam M; Eyileten T; Caglar K; Kirkpantur A; Celik T; Oguz Y; Vural A; Yenicesu M; Lindholm B; Stenvinkel P
Clin J Am Soc Nephrol; 2009 Mar; 4(3):535-41. PubMed ID: 19211665
[TBL] [Abstract][Full Text] [Related]
14. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
Esnault VL; Ekhlas A; Delcroix C; Moutel MG; Nguyen JM
J Am Soc Nephrol; 2005 Feb; 16(2):474-81. PubMed ID: 15615822
[TBL] [Abstract][Full Text] [Related]
15. Renoprotective efficacy of valsartan in chronic non-diabetic proteinuric nephropathies with renin-angiotensin system gene polymorphisms.
Lee YJ; Jang HR; Kim SG; Chae DW; Do JY; Lee JE; Huh W; Kim DJ; Oh HY; Kim YG
Nephrology (Carlton); 2011 Jul; 16(5):502-10. PubMed ID: 21303424
[TBL] [Abstract][Full Text] [Related]
16. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels.
Tomiyama H; Yamada J; Koji Y; Shiina K; Yoshida M; Yamashina A
Am J Hypertens; 2007 Dec; 20(12):1305-11. PubMed ID: 18047921
[TBL] [Abstract][Full Text] [Related]
17. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component.
Neri Serneri GG; Boddi M; Modesti PA; Coppo M; Cecioni I; Toscano T; Papa ML; Bandinelli M; Lisi GF; Chiavarelli M
Circ Res; 2004 Jun; 94(12):1630-7. PubMed ID: 15131005
[TBL] [Abstract][Full Text] [Related]
18. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.
Aslam S; Santha T; Leone A; Wilcox C
Kidney Int; 2006 Dec; 70(12):2109-15. PubMed ID: 17063175
[TBL] [Abstract][Full Text] [Related]
19. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
Yilmaz MI; Carrero JJ; Martín-Ventura JL; Sonmez A; Saglam M; Celik T; Yaman H; Yenicesu M; Eyileten T; Moreno JA; Egido J; Blanco-Colio LM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1174-81. PubMed ID: 20430947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
